NURPF   $8.58  7.25% Market Closed

NEUREN PHARMS LTD ORD
Last Events:

2023-08-06 Trend pattern changed from канал to расходящийся клин с наклоном вверх.

2023-08-06 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's lower than the signal line and falls. These factors mean that the growing period is over. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish recovery to bearish reversal. RSI indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: exit from the overbought zone.

2023-07-27 Trend pattern changed from расходящийся клин с наклоном вверх to канал.

2023-07-27 Signal in Stochastic changed from bullish recovery to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-04-29 Trend pattern changed from не определен to расходящийся клин с наклоном вверх.

2023-04-29 Signal in Stochastic changed from не определен to bullish recovery. The stochastic indicator is in overbought territory and it grows. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: main and signal line crossing.

2023-04-29 Signal in MACD changed from не определен to bullish recovery. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: entrance to the overbought zone.


Current temperature: 0.00
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy -
rsi ActivelyBuy - -
macd - - -
stoch - - -
ma20 ActivelyBuy - -
ma50 ActivelyBuy - -
ma100 ActivelyBuy ActivelyBuy -
ISIN NZNEUE0001S8
ceo Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
Website https://www.neurenpharma.com
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.